What is Delfi Diagnostics?
Delfi Diagnostics is a pioneering biotechnology firm specializing in the development of early cancer detection solutions through its innovative Fragmentomics Platform. By leveraging advanced machine learning algorithms and next-generation sequencing, the company analyzes cell-free DNA from liquid biopsy samples to identify malignant signatures with high sensitivity and specificity. Their product portfolio, which includes the FirstLookLung screening tool and the DELFI-TF treatment monitoring system, positions the company at the intersection of genomics, artificial intelligence, and clinical oncology. By providing scalable, non-invasive screening options, Delfi Diagnostics aims to transform standard cancer care protocols for healthcare systems, pharmaceutical partners, and patients globally.
How much funding has Delfi Diagnostics raised?
Delfi Diagnostics has raised a total of $325M across 2 funding rounds:
Series A
$100M
Series B
$225M
Series A (2021): $100M with participation from OrbiMed Advisors LLC, AV8 Ventures, Windham Venture Partners, Menlo Ventures, Samsara Biocapital, and Illumina Ventures
Series B (2022): $225M led by Brown Advisory, DFJ Growth, Eli Lilly and Company Pvt, and Point72
Key Investors in Delfi Diagnostics
OrbiMed Advisors LLC
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics with deep expertise in life sciences innovation cycles.
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, dedicated to building an ecosystem that translates capital into transformative technologies for human health.
DFJ Growth
DFJ Growth is a late-stage global venture capital firm that provides strategic capital to technology companies scaling rapidly and poised for market leadership.
What's next for Delfi Diagnostics?
With the infusion of capital from its latest financing round, Delfi Diagnostics is well-positioned to accelerate the clinical validation and commercial deployment of its diagnostic pipeline. The company is expected to focus on expanding its market reach for FirstLookLung while simultaneously deepening its research into multi-cancer detection capabilities. As the firm transitions from a development-focused entity to a commercial-stage leader, strategic priorities will likely include scaling operational infrastructure, strengthening partnerships with major healthcare providers, and navigating the regulatory pathways necessary for broader clinical adoption. The continued backing from top-tier life science investors provides the necessary runway to sustain long-term innovation in the competitive liquid biopsy sector.
See full Delfi Diagnostics company page
